Recent news on Fabrazyme

Genzyme's combination gene therapy shows potential for CNS disease  -  25 May 2007
DrugResearcher.com,Gaucher disease, Fabrazyme (agalsidase beta) for Fabry disease, Aldurazyme (laronidase) for MPS I and Myozyme (alglucosidase alfa) for Pompe disease.

Genzyme reports 57% profit spike  -  Apr 25, 2007
MarketWatchBOSTON (MarketWatch) -- Genzyme Corp. reported a 57% spike in first-quarter earnings early Wednesday, due largely to strong sales of such drugs as Fabrazyme

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  Apr 25, 2007
MSN MoneyGenzyme's three other treatments for lysosomal storage disorders showed continued strength in the first quarter: Sales of Fabrazyme(R) (agalsidase beta) for

Genzyme Gets Upgrade From Matrix  -  Mar 15, 2007
Houston Chronicle,Genzyme products include Renagel for kidney disease, Fabrazyme for Fabry disease and Thyrogen thyroid cancer. It is currently developing Myozyme for the

Cashing in on 'orphans'  -  Mar 16, 2007
CNNMoney.comOne is Fabrazyme, a medication for a disease similar to Gaucher that's known as Fabry. The other is Myozyme, a drug for Pompe disease, a debilitating and

Genzyme Reports Financial Results for Fourth Quarter of 2006 and ...  -  Feb 14, 2007
Oxfordshire Bioscience Network (press release),Sales of Fabrazyme® (agalsidase beta) are expected to reach $415-$425 million this year, compared with $359 million in 2006. Fabrazyme’s growth is being

Genzyme posts strong financials, despite AnorMed charges  -  Feb 15, 2007
Pharma Times (subscription),...driven by sales of Gaucher disease treatment Cerezyme (imiglucerase), up 13% to $261.8 million and Fabry disease drug Fabrazyme (agalsidase beta),

Stem Cell Company Appoints Dr. Pedro Huertas as Chief Development ...  -  Feb 20, 2007
HispanicBusiness.com,He worked as a director of strategic development for Gnezyme, where he registered Fabrazyme, which garnered sales of $305 million in 2005 for the treatement

Genzyme Has Fourth-Quarter Loss; Sees Higher Sales (Update2)  -  Feb 14, 2007
BloombergSales of Fabrazyme for the rare Fabry disease are expected to reach $415 million to $425 million this year, up from $359 million in 2006.

Advanced Cell Technology Names Noted Biotech Industry Executive Dr ...  -  Feb 12, 2007
dBusinessNews San Francisco (press release),...biologics license application (BLA) to register Fabrazyme, which achieved worldwide sales of $305 million in 2005 for the treatment of Fabry disease.

Zacks.com Announces That Nadine Wong Highlights: Genzyme  -  Feb 2, 2007
Business Wire (press release),Nadine Wong and her team anticipate a continued strong Myozyme launch, as well as solid Cerezyme and Fabrazyme sales performance.

Largest-ever Fabry study shows earlier treatment with (Pr ...  -  Jan 17, 2007
PipelineReview.com (press release),The study, entitled Agalsidase-Beta Therapy for Advanced Fabry Disease, has shown that early treatment with the enzyme replacement therapy Fabrazyme at 1

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),Fourth-quarter sales of Fabrazyme® (agalsidase beta) for Fabry disease were $96 million, up 18 percent from $82 million in the same quarter a year ago.

Genzyme Sales Rise in 4Q  -  Jan 9, 2007
BusinessWeekGenzyme reported sales of Fabrazyme at $96 million, up 18 percent from $82 million last year. Fabrazyme is the only drug on the market to treat Fabry

Genzyme's revenue up 17 percent in quarter  -  Jan 9, 2007
Boston Globe,Fourth quarter sales of Fabrazyme for Fabry disease were $96 million, up 18 percent from $82 million last year. The company said full-year sales of the drug

Genzyme expects 2007 profit to rise on drug sales  -  Jan 9, 2007
ReutersFourth-quarter sales of Fabrazyme, the company's drug to treat Fabry disease, which causes blood fats to build up in blood vessels, rose 18 percent to $96

Genzyme reports 17% jump in fourth-quarter revenue  -  Jan 9, 2007
MarketWatchFabrazyme drug sales were up 18% from last year to $96 million. The biotech bellwether went on to forecast that 2007 revenue will come in between $3.6

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional